Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-mannuronic acid is a uronic acid monosaccharide and a key monomeric unit of alginate, a natural polysaccharide found in brown algae. It is commonly used in its sodium salt form for biomedical applications, particularly as a component in the production of alginate hydrogels for drug delivery systems. These hydrogels are valued for their ability to encapsulate drugs and enable controlled release, making them useful in research on cancer, bacterial infections, and cardiovascular diseases[4]. β-D-Mannuronic Acid (sometimes referred to as M2000) has also been studied as an experimental non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive properties and potential antidiabetic, cardioprotective, and anti-tumoral effects[7][5]. The mechanism of action involves modulation of immune responses; however, specific molecular targets are not fully established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-mannuronic acid.